Efficacy of Beclomethasone Dipropionate in Lowering Fecal Calprotectin Levels in Patients with Ulcerative Colitis in Clinical Remission and at Risk of Relapse: The Becalcu Randomized, Controlled Trial

Introduction: Identifying novel treatment strategies for patients with ulcerative colitis (UC) and at risk of relapse is critical. The objective of this study was to assess the efficacy of beclomethasone dipropionate (BDP) in lowering fecal calprotectin (FC) levels in UC patients in clinical remissi...

Full description

Bibliographic Details
Authors: Ginard, D, Barreiro-de Acosta, M, Nos, P, Moraleja, I, Nuñez, FM, Aldeguer, X, Echarri, A, Villoria, A, Riestra, S, Watts, MMB, González-Lama, Y, Royo, V, Ferreiro-Iglesias, R, Iborra, M, Elorza, A, Fernandez-Pordomingo, A, Sans, M
Format: article
Status:Published version
Publication Date:2024
Country:España
Institution:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repository:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:i3pt.fundanetsuite.com:p5294
Online Access:https://i3pt.portalinvestigacion.com/publicaciones/5294
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85206316600&doi=10.1159%2f000540792&partnerID=40&md5=1fb82e749bfd84cabbcb156b95e698b1
Access Level:Open access
Keyword:Ulcerative colitis
Fecal calprotectin
Beclomethasone dipropionate
Remission
Description
Summary:Introduction: Identifying novel treatment strategies for patients with ulcerative colitis (UC) and at risk of relapse is critical. The objective of this study was to assess the efficacy of beclomethasone dipropionate (BDP) in lowering fecal calprotectin (FC) levels in UC patients in clinical remission and at risk of relapse. Methods: This multicenter study comprised a double-blind, randomized, placebo-controlled phase (part I) and an open-label, non-randomized phase (part II). Eligible participants with UC in clinical remission treated with 5-aminosalicylic acid and with FC levels >= 250 mu g/g were randomized to receive 5 mg/day of BDP or placebo for 4 weeks (part I). At week 5, patients with FC >= 100 mu g/g were treated with 5 mg/day of BDP for 4 weeks (part II), and FC levels were tested at week 9. Results: Forty-three patients were randomized: 22 received BDP (group A) and 21 placebo (group B). At week 4, 13 patients (59.1%) in group A and 3 (17.6%) in group B had FC levels <100 mu g/g (p value = 0.010). In the double-blind phase of the study, no patient relapsed in group A and 4 in group B (p value = 0.049). Both treatment groups showed a favorable safety profile, with the most common adverse events being gastrointestinal disorders. Conclusion: In this multicenter, randomized clinical trial including patients with UC in clinical remission but with elevated FC, BDP was efficacious in reducing FC and well-tolerated.

Similar Items